IRIDEX has obtained FDA's 510(k) approval and CE mark for its non-invasive laser delivery system, designed for treating serious retinal diseases.
Using MicroPulse technology, the new TxCell Scanning laser delivery system saves time in a variety of laser photocoagulation procedures by allowing physicians to deliver the laser in a multi-spot scanning mode.
IRIDEX president and CEO Will Moore said broadening market acceptance for medical technologies, in general, involves effective clinical results, ease of use for the physicians and more efficient use of time.
"TxCell can deliver all three benefits and is an important step in accelerating the adoption of our proprietary MicroPulse technology as it applies to several clinical procedures," Moore added.
Eye Clinic Ospedale Sacco ophthalmology and chairman Giovanni Staurenghi said, "TxCell Scanning Laser Delivery System with the IQ 577 offers an intuitive and versatile way to deliver several advanced laser modalities."